BioNTech Completes Acquisition of CureVac to Enhance mRNA Technology

BioNTech SE has successfully finalized its acquisition of CureVac N.V., completing the exchange offer that significantly enhances BioNTech’s capabilities in messenger RNA (mRNA) technology. As of the conclusion of the offering period on December 18, 2025, approximately 86.75% of CureVac’s shares had been tendered. BioNTech anticipates completing the compulsory acquisition of the remaining shares by January 2026 as part of a strategic reorganization.

This acquisition is designed to bolster BioNTech’s proprietary technologies in mRNA design and delivery formulations, reinforcing its established position in the global mRNA industry. The company aims to leverage these advancements to further its oncology strategy, which includes mRNA-based cancer immunotherapy candidates and the bispecific antibody candidate pumitamig (BNT327/BMS986545), developed in collaboration with Bristol Myers Squibb Company.

Prof. Ugur Sahin, M.D., CEO and Co-Founder of BioNTech, expressed gratitude towards all involved in the acquisition, noting that it deepens their mRNA technology platform and expands their potential to develop innovative therapeutic drugs. “With an approved mRNA product and multiple late-stage programs spanning distinct mechanisms of action, we are advancing a new generation of medicines aimed at delivering meaningful benefits for patients,” he stated.

The acquisition also marks a significant collaboration between two pioneering firms in Germany’s mRNA sector. Helmut Jeggle, Chairman of the BioNTech Supervisory Board, emphasized the synergy of vision and technology that emerges from this merger. He highlighted the importance of both companies being founded in Germany and supported by dedicated long-term oriented family offices that foster entrepreneurial ventures.

Following the acquisition’s closure, the Management Board of CureVac SE will consist of Prof. Ugur Sahin, M.D., Sierk Poetting, Ph.D., and Ramón Zapata-Gomez. The previous members of the CureVac Management Board have resigned to facilitate this transition. Despite this change, CureVac will maintain its existing organizational processes to ensure business continuity while BioNTech conducts strategic, operational, and scientific evaluations to define the future structure and portfolio of the combined entity.

According to Computershare Trust Company, N.A., the exchange agent for the Offer, a total of 195,341,219 CureVac shares have been validly tendered, representing approximately 86.75% of the company’s issued and outstanding shares. Following the completion of the post-offer reorganization, CureVac shares will no longer be available for trading.

BioNTech, headquartered in Mainz, Germany, is recognized as a global leader in next-generation immunotherapy, focusing on innovative treatments for cancer and other serious diseases. Its diverse oncology product portfolio includes mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies such as antibody-drug conjugates and CAR T cell therapies.

As BioNTech continues to expand its influence in the mRNA landscape, the integration of CureVac marks a pivotal moment in its mission to pioneer novel biopharmaceuticals. For further details about the acquisition and ongoing developments, interested parties can visit www.BioNTech.com.

In consideration of future prospects, BioNTech advises that this announcement contains forward-looking statements regarding the anticipated benefits and outcomes of the acquisition. Investors should be aware of potential risks and uncertainties that could impact future performance, including regulatory changes and market conditions.